Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Shock, Septic × Clear all

Phase

Phase 3 4 Phase NA 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 117 Neoplasms 101 Prostatic Neoplasms 75 Carcinoma, Non-Small-Cell Lung 74 Colorectal Neoplasms 72 Carcinoma, Hepatocellular 67 Leukemia, Myeloid, Acute 56 Stomach Neoplasms 51 Neoplasm Metastasis 50 Lung Neoplasms 48 Precursor Cell Lymphoblastic Leukemia-Lymphoma 44 Pancreatic Neoplasms 40 Recurrence 36 Head and Neck Neoplasms 31 Rectal Neoplasms 30 Colonic Neoplasms 30 Leukemia 29 Multiple Myeloma 28 Ovarian Neoplasms 25 Lymphoma 25 Squamous Cell Carcinoma of Head and Neck 23 Hematologic Neoplasms 23 Melanoma 21 Urinary Bladder Neoplasms 20 Liver Neoplasms 20 Myelodysplastic Syndromes 19 Lymphoma, Large B-Cell, Diffuse 19 Esophageal Neoplasms 19 Polycystic Ovary Syndrome 18 Uterine Cervical Neoplasms 16

Interventions

Saline Solution 1 Methylene Blue 1 Contraceptives, Oral 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06005558 2024-07-05

Low Dose Versus High Dose Methylene Blue in Septic Patients

National Cancer Institute, Egypt

Phase 2/3 Completed

Shock, Septic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡